The Drug Regulatory Authority of Pakistan (DRAP) has rolled out a new set of guidelines for medicine registration, aligning the country’s pharmaceutical approval process more closely with World Health Organization standards. The DRAP medicine registration guidelines are intended to bring greater transparency and consistency to how new drugs are reviewed and approved for sale across Pakistan.
Officials say the update responds to long-standing concerns from both local manufacturers and multinational pharmaceutical companies about inconsistent documentation requirements and unpredictable review timelines. Under the previous framework, applicants often faced delays caused by unclear expectations about what supporting data or paperwork a registration dossier needed to include, leading to repeated back-and-forth between DRAP and applicants before a decision could be reached.
What the New Guidelines Change
The revised framework is built around three main goals: transparency in how applications are evaluated, consistency with international regulatory standards, and a streamlined process that reduces unnecessary delays. DRAP has said the guidelines were developed with reference to WHO’s own recommended practices for national drug regulatory authorities, an approach meant to make Pakistan’s approval process more predictable for companies that also register products in other markets.
A key feature of the update is that applicants will now receive fuller information support before they even submit a registration request. This includes clearer documentation checklists and defined criteria for what regulators are looking for at each stage of review, rather than applicants discovering gaps only after submission. DRAP says this pre-registration clarity should cut down on the resubmissions and clarification requests that have historically slowed the process down.
Why This Matters for Access to Medicines
The expected outcome, according to DRAP, is a more harmonized review process nationwide and faster access to quality medicines for patients. A registration system that moves predictably matters directly to public health outcomes, since delays in approving new drugs — including generics and updated formulations of existing treatments — can leave gaps in the local availability of needed medicines.
For pharmaceutical manufacturers, the shift toward WHO-aligned standards could also make it easier to pursue export opportunities, since regulatory frameworks that mirror international norms are generally viewed more favorably by foreign buyers and partner agencies. Industry groups have generally welcomed moves toward standardization, though the real test will be whether DRAP can maintain the promised timelines once application volumes pick up.
The guidelines arrive as provincial governments continue to expand public health-linked initiatives elsewhere, including Punjab’s plan to build a cancer hospital in every division, underscoring a broader push across federal and provincial institutions to strengthen healthcare access and regulatory reliability at the same time.